Camouflage mechanism of cancer cells in Hodgkin's lymphoma decoded
Curt Meyer Memorial Prize for Dr. Stephan Mathas and Dr. Martin Janz
The phenotype of Hodgkin lymphoma cells is a riddle that has puzzled pathologists for years. It was not until 1994, some 160 years after the disease was first described by the British physician Sir Thomas Hodgkin (1832), that - using molecular biological methods - scientists discovered that the lymphoma bearing his name originates from the white blood cells, the B cells.
In their article, Dr. Janz and Dr. Mathas of the research group of Professor Bernd Dörken (MDC/Charité) were able to show that several molecular defects in the B cells are responsible for the unique phenotype of the disease. First, in Hodgkin/Reed-Sternberg cells which have evolved from the B cells, the genetic program that steers the maturation of the B cells and maintains their identity is perturbed. One of the main regulators of this program, E2A, is inhibited in Hodgkin lymphoma cells by two antagonists, Id2 and ABF-1. The researchers showed that this mechanism inhibits the gene expression pattern of B cells. Moreover, through the inhibition of E2A in Hodgkin lymphoma cells, genes are switched on that are not typical for B cell development.
Since 1988, the Curt Meyer Memorial Prize has been awarded annually by the Berlin Cancer Society to young scientists from Berlin for outstanding publications in the field of clinical and experimental oncology. The prize is named after Dr. Curt Meyer, a physician and health official of the Berlin Senate who was born in Herleshausen/Thuringia in 1891. In 1944, he was deported to Auschwitz where he as prisoner took care of fellow detainees suffering from epidemic disease. He survived the concentration camp and after the war dedicated himself to public health, including the care of cancer patients. He was the founder of several medical societies, including the Berlin State Committee against Cancer out of which the Berlin Cancer Society has evolved. Curt Meyer died in 1984 at the age of 93.
*Intrinsic inhibition of E2A by ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.